Skip to content

Study · Non-randomized trial · n = 22 · 1994

3 results

Anomalous growth hormone response to vasoactive intestinal peptide and peptide histidine methionine in patients with prolactinoma or hypothalamic hyperprolactinemia.

Watanobe H, Tamura T, Takahashi K

Neuropeptides1 Aug 1994Cited by 2 (Europe PMC)

PMID7991068 (opens in a new tab)DOI10.1016/0143-4179(94)90054-x (opens in a new tab)PepBankPUB-07991068
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In 22 patients with hyperprolactinemia, thirteen (59%) showed a paradoxical rise in growth hormone after VIP.

    In plain wordsIn 22 patients with high prolactin, VIP caused an unexpected rise in growth hormone in thirteen.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseParadoxical GH rise after VIP
    Study

    n = 22

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms · intravenous bolusAs given in this study (human).

    Source sentences

    Summary
    Thirteen (59%) patients showed a paradoxical rise in GH after VIP
    2 context sentences
    Summary · context
    We examined a possible GH-releasing activity of vasoactive intestinal peptide (VIP) and its homologous peptide, peptide histidine methionine (PHM), in 22 patients with hyperprolactinemia (HPRL) who comprised 19 cases of prolactinoma (PRLoma) and 3 cases of hypothalamic HPRL.
    Summary · context
    Each patient underwent iv bolus injections of VIP (100 micrograms) and PHM (100 micrograms) on separate days, and plasma levels of GH and PRL were measured.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with hyperprolactinemia, the prolactin-releasing activity of VIP was subnormal.

    In plain wordsIn patients with high prolactin, VIP released less prolactin than normal.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseProlactin-releasing activity of VIP
    Study

    n = 22

    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    100 micrograms · intravenous bolusAs given in this study (human).

    Source sentences

    Summary
    In agreement with previous reports, the PRL-releasing activity of VIP and PHM in our patients with HPRL were subnormal.
    2 context sentences
    Summary · context
    We examined a possible GH-releasing activity of vasoactive intestinal peptide (VIP) and its homologous peptide, peptide histidine methionine (PHM), in 22 patients with hyperprolactinemia (HPRL) who comprised 19 cases of prolactinoma (PRLoma) and 3 cases of hypothalamic HPRL.
    Summary · context
    Each patient underwent iv bolus injections of VIP (100 micrograms) and PHM (100 micrograms) on separate days, and plasma levels of GH and PRL were measured.
  3. 03HumanNon-randomized trialEfficacy outcome

    All 3 patients with hypothalamic hyperprolactinemia had a significant rise in growth hormone after VIP.

    In plain wordsAll 3 patients with hypothalamic high prolactin showed a clear growth hormone rise after VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseGH rise after VIP in hypothalamic hyperprolactinemia
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms · intravenous bolusAs given in this study (human).

    Source sentences

    Summary
    It is to be noted that all the 3 patients with hypothalamic HPRL responded to VIP with a significant rise in GH.
    2 context sentences
    Summary · context
    We examined a possible GH-releasing activity of vasoactive intestinal peptide (VIP) and its homologous peptide, peptide histidine methionine (PHM), in 22 patients with hyperprolactinemia (HPRL) who comprised 19 cases of prolactinoma (PRLoma) and 3 cases of hypothalamic HPRL.
    Summary · context
    Each patient underwent iv bolus injections of VIP (100 micrograms) and PHM (100 micrograms) on separate days, and plasma levels of GH and PRL were measured.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.